In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

The global Liquid Biopsy Market is valued at USD 11.41 Billion in 2024 and is projected to reach a value of USD 30.65 Billion ...

Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

Plants produce a wide diversity of compounds. Broadly, these are separated into primary metabolites, which are necessary for ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

23 analysts are following Illumina and have set target prices ranging from $70.0 to $185.0 per share. On average, they have given the company a rating of buy. At today's prices, ILMN is trading -7.75% ...